We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Eremid® Genomic Services Founded Following VC Investment as Cornerstone of Expanding Biotech Hub


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Eremid® Genomic Services Founded Following VC Investment as Cornerstone of Expanding Biotech Hub"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eremid® Genomic Services, LLC (“Eremid”), formerly Eremid Research Services, Inc., has been acquired by Coddle Creek Capital (“CCC”) and is under new commercial management. CCC has made a multi-million-dollar investment in Eremid, enabling an expanded research offering focused on the intersection of genomics in the areas of human health, agriculture, plant based nutrition and longevity. Coddle Creek Capital is an early-stage life science venture capital fund partnering with academic Principal Investigators to move their research into commercial enterprises. Focusing on quality and service, customers can expect Eremid’s world-class scientific staff to deliver high-quality data using the latest generation of genomics instruments and automation, meeting a growing demand for high-end genomics/research across multiple markets. The company will be a key partner and resource for the rapidly growing biotech hub being built on the North Carolina Research Campus, and for the local and wider genomics community.


Originally spun out as the commercial arm of the David H. Murdock Research Institute, the new investment from CCC will see Eremid refocus on becoming a high-end, scientifically driven genomics partner. Boosted by rapidly-evolving Next Generation Sequencing technologies, research and applications in this growing branch of molecular biology increasingly demand higher quality, reliability, and accuracy in data and interpretation. Eremid’s goal is to provide access to and guidance on better use of these technologies, and its experience in delivering complex genomics projects and bioinformatic analyses places it as the perfect CRO partner to meet this need.


In addition to Eremid, CCC has been a key investor, advisor and/or founder of several co-located companies that will form part of the expanding biotech hub, including:

  • BrightPath Labs: A highly advanced AI-driven drug manufacturer accelerating US Pharmaceutical independence via advanced manufacturing technology.
  • Salubrent Pharma Services: An analytical and consultation services CDMO focused on advancing the aseptic sterile fill & finish formulation and manufacturing sector.
  • SNP Therapeutics: A Precision Nutrition company, spun out from the University of North Carolina Chapel Hill Nutritional Research Institute in Kannapolis, NC.

 

Adding a new and already successful company to its portfolio will bolster Coddle Creek Capital’s position as an early phase investor and help the new biotech hub gain traction.


Julian Abery, Chief Business Officer at Eremid commented: “This is an exciting time of growth and development for us. With the support of Coddle Creek Capital, Eremid promises to become a best-in-class genomics CRO. We will deliver scientific excellence to our customers by leveraging decades of research experience and the latest technologies, while making no compromises in our processes. We will focus on areas that influence human health and longevity, including agbiotech, nutrition, and immunooncology research.”


John Allen, General Partner at Coddle Creek Capital, added: “I’m delighted for us to add Eremid Genomic Services to our portfolio. Eremid already provides high-end NGS services to the market, meeting a demand for absolute expertise, reliability, and data quality. With our investment, the company will be able to leverage its expertise and instrumentation to provide a truly exceptional service to the wider genomics community and help catalyze further developments in the local area.”

  

Advertisement